MarketPulse

Nuvaxovid

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Outperforms Moderna mRNA Vaccine in Tolerability Study

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.
SNYMRNAclinical trialCOVID-19 vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Shows Superior Safety Profile Against Moderna's mRNA Vaccine

Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.
SNYMRNAclinical trialCOVID-19 vaccine